Abstract
An important group of signalling molecules operate through a pathway which is slightly different from that described in Chap. 1: their receptors do not present tyrosine kinase activity but are coupled to a cytoplasmic tyrosine kinase which ensures, after receptor activation, the transduction of a signal leading to the transcription of target genes. The main signalling pathway downstream the activation of these receptors by their ligands involves cytoplasmic JAK (just another kinase, now Janus kinase) proteins and STAT (signal transducer and activator of transcription) transcription factors, but the activation of other kinases is sometimes possible, with connections with the MAP kinases (Chap. 2) and the PI3 kinase (Chap. 3) pathways.
Whereas the word ‘cytokine’ designates often a large variety of signalling proteins, including growth factors (Chap. 1), TNF-related factors and chemokines (Chap. 6), we will adopt a mechanistic definition and restrict this denomination to the ligands of membrane receptors devoid of tyrosine kinase activity but coupled with cytoplasmic tyrosine kinases. This includes most interleukins and interferons, but excludes many signalling molecules that activate other receptors, such as tyrosine kinase receptors, death receptors, interleukin-1 and toll-like receptors, etc. The cytokines envisaged in this chapter may be involved in multiple cell processes: proliferation and differentiation of blood cells, immunity and inflammation, body weight and size control, antiviral defences, etc.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009;27:4422–32.
Constantinescu SN, Girardot M, Pecquet C. Mining for JAK–STAT mutations in cancer. Trends Biochem Sci. 2007;33:122–31.
Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, Zhou YJ, Visconti R, O’Shea JJ. Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol. 2001;13:363–73.
Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007;13:5665–9.
Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904–10.
Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors – an intimate relationship. Biochem Pharmacol. 2006;72:1538–46.
Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591–4.
Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol. 1995;13:369–98.
Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell. 1994;76:253–62.
Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 2013;12:611–29.
Moutoussamy S, Kelly PA, Finidori J. Growth-hormone-receptor and cytokine-receptor-family signaling. Eur J Biochem. 1998;255:1–11.
Mullally A, Ebert BL. Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma. J Clin Oncol. 2012;30:4168–70.
Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178:2623–9.
O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109:S121–31.
O’Sullivan LA, Liongue C, Lewis RS, Stephenson SEM, Ward AC. Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease. Mol Immunol. 2007;44:2497–506.
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O’Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223:132–42.
Quintás-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19:1933–40.
Renauld JC. Class II, cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol. 2003;3:667–76.
Santos CI, Costa-Pereira AP. Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta. 1816;2011:38–49.
Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science. 1995;268:251–5.
Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics – an update. Eur J Pharmacol. 2008;579:1–12.
Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006;97:439–47.
Zhang J, Li H, Yu JP, Wang SE, Ren XB. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer. 2012;130:1971–80.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Robert, J. (2015). Cytokines Pathway. In: Textbook of Cell Signalling in Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-14340-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-14340-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-14339-2
Online ISBN: 978-3-319-14340-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)